LAWRENCEVILLE, N.J.,
Dec. 17, 2015 /PRNewswire/
-- Celsion Corporation (NASDAQ: CLSN), a fully-integrated
oncology company focused on the development of a portfolio of
innovative cancer treatments, including directed chemotherapies,
immunotherapies and RNA- or DNA-based therapies for the treatment
of cancer and other difficult-to-treat diseases, today announced
the appointment of Donald P. Braun,
Ph.D. and Andreas Voss, M.D., to the
Company's Board of Directors.
"We are delighted and fortunate to welcome Dr. Voss and Dr.
Braun, both of whom bring a wealth of experience and knowledge in
oncology drug development to our Board," said Michael H. Tardugno, Celsion's chairman,
president and chief executive officer. "Dr. Voss's international
clinical experience and direct involvement with the development of
Avastin® and Dr. Braun's extensive experience in pre-clinical
research and in particular with IL-12 will provide relevant and
current insights for Celsion's strategic framework and will be
invaluable as we continue forward with the development of GEN-1,
Celsion's IL-12 immunotherapy candidate that has demonstrated a
synergistic anti-cancer effect in preclinical combination studies
with Avastin® and Doxil®."
Dr. Braun brings over 30 years of research expertise in
oncology, with a focus on immunotherapy and the effectiveness and
impact of chemotherapy protocols on various cancers and tumor
types, and currently serves as Vice President Translational
Research and Chief Science Officer at the Cancer Treatment Centers
of America. Prior to his current role, he was the Scientific
Director of the Cancer Center and Professor of Medicine and
Immunology at Rush Medical College in Chicago, and the Administrative Director of
the Cancer Institute and a Professor of Surgery with tenure at the
Medical College of Ohio. Dr. Braun has been appointed to and
served on more than a dozen federal government and public advisory
committees on oncology and immunology. He received his Ph.D. in
Immunology and Microbiology from the University of Illinois at the Medical Center in
Chicago.
Dr. Voss currently serves as Vice President of Clinical Affairs
in Europe at Caris Life Sciences,
a biotechnology company focused on implementing personalized
medicine in oncology through its liquid biopsy technology. Prior to
joining Caris in 2010, he was responsible for the global clinical
development of Avastin® and a member of the Corporate Drug Safety
Board at F. Hoffmann-La Roche. Before joining Roche in 2006, he was
Medical Director for the Lung Cancer Disease Area at AstraZeneca,
and from 2000 to 2003, he was the Medical Director for
Anti-infectives and Oncology at Bayer GmbH. From 1996 to
2000, Dr. Voss was Head of Medical Research, Oncology at Asta
Medica AG. Dr. Voss received his M.D. from the University of
Hamburg Medical School and was a postdoctoral fellow at the
University of California at San Diego.
He is board certified in internal medicine.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer and
in Phase II development for the treatment of recurrent chest wall
breast cancer. Celsion's pipeline also includes GEN-1, a
DNA-based immunotherapy for the localized treatment of ovarian and
brain cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies, including TheraPlas™ and
TheraSilence™. For more information on Celsion, visit our
website: http://www.celsion.com.
Celsion wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of
1995. Readers are cautioned that such forward-looking
statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and
development activities and in clinical trials; FDA and regulatory
uncertainties and risks; the significant expense, time, and risk of
failure of conducting clinical trials; possible acquisitions or
licenses of other technologies, assets or businesses; possible
actions by suppliers, competitors, regulatory authorities; and
other risks detailed from time to time in the Celsion's periodic
reports and prospectuses filed with the Securities and Exchange
Commission. Celsion assumes no obligation to update or
supplement forward-looking statements that become untrue because of
subsequent events, new information or otherwise.
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion Media Contacts
Harriet Shelare
Director, Communications
806-483-1721
hshelare@celsion.com
Bill Berry
Berry & Company
212-253-8881
bberry@berrypr.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/celsion-announces-appointment-of-two-new-members-to-its-board-of-directors-300194187.html
SOURCE Celsion Corporation